Abstract
Diabetic foot ulcer is a common complication in diabetic patients and the outcome of foot ulcer depends on the severity of ulcer and combined infection such as osteomyelitis. So antibiotics targeting Gram positive cocci including Staphylococcus aureus have been used frequently. However, during the antibiotic therapy, diverse adverse reactions could be happened including red man syndrome, chest pain, hypotension, thrombocytopenia, neutropenia and drug eruption. Among these reactions, hematologic adverse events such as pancytopenia are rare and it could be lethal if happened. This article reports a case of pancytopenia associated with vancomycin in treating the diabetic patient with infected foot ulcer.
References
2. Waugh NR. Amputations in diabetic patients-a review of rates, relative risks and resource use. Community Med. 1988. 10:279–288.
3. Bloomgarden ZT. American Diabetes Association 60th Scientific Sessions, 2000: the diabetic foot. Diabetes Care. 2001. 24:946–951.
4. Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJ. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care. 1998. 21:1071–1075.
5. Shaw JE, Boulton AJ. The pathogenesis of diabetic foot problems: an overview. Diabetes. 1997. 46:Suppl 2. S58–S61.
6. Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW. Assessment and management of foot disease in patients with diabetes. N Engl J Med. 1994. 331:854–860.
7. Young LS. Hematologic effects of linezolid versus vancomycin. Clin Infect Dis. 2004. 38:1065–1066.
8. Rocha JL, Kondo W, Baptista MI, Da Cunha CA, Martins LT. Uncommon vancomycin-induced side effects. Braz J Infect Dis. 2002. 6:196–200.
9. Bay A, Oner AF, Dogan M, Caksen H. A child with vancomycin-induced thrombocytopenia. J Emerg Med. 2006. 30:99–100.
10. Domen RE, Horowitz S. Vancomycin-induced neutropenia associated with anti-granulocyte antibodies. Immunohematol. 1990. 6:41–43.
11. Segarra-Newnham M, Tagoff SS. Probable vancomycin-induced neutropenia. Ann Pharmacother. 2004. 38:1855–1859.
12. Schwartz MD. Vancomycin-induced neutropenia in a patient positive for an antineutrophil antibody. Pharmacotherapy. 2002. 22:783–788.
13. Mizon P, Kiefel V, Mannessier L, Mueller-Eckhardt C, Goudemand J. Thrombocytopenia induced by vancomycin-dependent platelet antibody. Vox Sang. 1997. 73:49–51.
14. Domen RE. Vancomycin-induced cytopenias. Arch Intern Med. 1992. 152:413–414.
15. Howard CE, Adams LA, Admire JL, Chu MA, Alred GL. Vancomycin-induced thrombocytopenia: a challenge and rechallenge. Ann Pharmacother. 1997. 31:315–318.
16. Sanche SE, Dust WN, Shevchuk YM. Vancomycin-induced neutropenia resolves after substitution with teicoplanin. Clin Infect Dis. 2000. 31:824–825.
17. Lipsky BA, Berendt AR, Deery HG, Embil JM, Joseph WS, Karchmer AW, LeFrock JL, Lew DP, Mader JT, Norden C, Tan JS. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2004. 39:885–910.
18. Nelson EA, O'Meara S, Golder S, Dalton J, Craig D, Iglesias C. DASIDU Steering Group. Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabet Med. 2006. 23:348–359.